Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study (Q45168352)
Jump to navigation
Jump to search
scientific article published in December 2004
Language | Label | Description | Also known as |
---|---|---|---|
English | Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study |
scientific article published in December 2004 |
Statements
1 reference
Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study (English)
1 reference
F Duffaud
1 reference
M Borner
1 reference
P Chollet
1 reference
J B Vermorken
1 reference
J Bloch
1 reference
M Degardin
1 reference
F Rolland
1 reference
C Dittrich
1 reference
B Baron
1 reference
D Lacombe
1 reference
P Fumoleau
1 reference
EORTC-New Drug Development Group/New Drug Development Program
1 reference
1 December 2004
1 reference
1 reference
40
1 reference
18
1 reference
2748-2752
1 reference
Identifiers
1 reference
1 reference